Opportunity ID: 335738

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-21-334
Funding Opportunity Title: Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.394 — Cancer Detection and Diagnosis Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Sep 16, 2021
Last Updated Date: Sep 16, 2021
Original Closing Date for Applications: Jun 11, 2024
Current Closing Date for Applications: Jun 11, 2024
Archive Date: Jul 17, 2024
Estimated Total Program Funding:
Award Ceiling: $600,000
Award Floor:

Eligibility

Eligible Applicants: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Others (see text field entitled “Additional Information on Eligibility” for clarification)
State governments
County governments
City or township governments
Special district governments
Public housing authorities/Indian housing authorities
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Native American tribal governments (Federally recognized)
Public and State controlled institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium (PCDC), to conduct research on early detection of pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions to identify those patients who are at high risk of progression to cancer. The PCDC will continue to address one of the four research priorities identified in the National Cancer Institute’s 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma. The PCDC will support research for the development and testing of new molecular and imaging biomarkers for detecting PDAC early and for identifying those patients at high risk of PDAC (because of genetic factors or presence of precursor lesions) who could be candidates for early intervention. The PCDC-RUs will consist of multi-disciplinary teams and will undertake studies to: identify and test biomarkers measurable in bodily fluids for early detection of PDAC and/or its precursor lesions; determine which pancreatic cysts are likely to progress to cancer; develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC; use machine learning and computational approaches towards biomarker discovery and/or validation; and conduct biomarker validation studies. The PCDC-RUs will also collect longitudinal biospecimens for building a biorepository. Each PCDC-RU is expected to participate in collaborative activities with other PCDC-RUs and share ideas, biospecimens and data within the Consortium. The other scientific component of the PCDC will be the Management and Data Coordination Unit (MDCU). The PCDC-MDCU will provide support toward study design, protocol development, statistical analysis, coordination, harmonization, data management and stewardship for the trans-PCDC collaborative projects, including biorepository building effort. The PCDC-MDCU will also supp
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-21-334.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email:OERWebmaster03@od.nih.gov

Version History

Version Modification Description Updated Date

Folder 335738 Full Announcement-PAR-21-334 -> PAR-21-334-Full-Announcement.pdf

Packages

Agency Contact Information: NIH OER Webmaster
OERWebmaster03@od.nih.gov
Email: OERWebmaster03@od.nih.gov
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-G Use for due dates on or before January 24, 2023 PKG00270408 Nov 18, 2021 Jan 24, 2023 View
FORMS-F Use for due dates on or before January 24, 2022 PKG00268964 Oct 15, 2021 Jan 24, 2022 View
FORMS-H Use for due dates on or after January 25, 2023 PKG00277951 Nov 04, 2022 Jun 11, 2024 View

Package 1

Mandatory forms

335738 RR_SF424_5_0-5.0.pdf

335738 PHS398_CoverPageSupplement_5_0-5.0.pdf

335738 RR_OtherProjectInfo_1_4-1.4.pdf

335738 PerformanceSite_4_0-4.0.pdf

335738 RR_KeyPersonExpanded_4_0-4.0.pdf

335738 PHS398_ResearchPlan_4_0-4.0.pdf

335738 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

335738 RR_Budget_3_0-3.0.pdf

335738 RR_SubawardBudget30_3_0-3.0.pdf

335738 PHS398_ModularBudget_1_2-1.2.pdf

335738 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

335738 RR_SF424_2_0-2.0.pdf

335738 PHS398_CoverPageSupplement_5_0-5.0.pdf

335738 RR_OtherProjectInfo_1_4-1.4.pdf

335738 PerformanceSite_2_0-2.0.pdf

335738 RR_KeyPersonExpanded_2_0-2.0.pdf

335738 PHS398_ResearchPlan_4_0-4.0.pdf

335738 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

335738 RR_Budget_1_4-1.4.pdf

335738 RR_SubawardBudget30_1_4-1.4.pdf

335738 PHS398_ModularBudget_1_2-1.2.pdf

335738 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 3

Mandatory forms

335738 RR_SF424_5_0-5.0.pdf

335738 PHS398_CoverPageSupplement_5_0-5.0.pdf

335738 RR_OtherProjectInfo_1_4-1.4.pdf

335738 PerformanceSite_4_0-4.0.pdf

335738 RR_KeyPersonExpanded_4_0-4.0.pdf

335738 PHS398_ResearchPlan_5_0-5.0.pdf

335738 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

335738 RR_Budget_3_0-3.0.pdf

335738 RR_SubawardBudget30_3_0-3.0.pdf

335738 PHS398_ModularBudget_1_2-1.2.pdf

335738 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-12T03:03:47-05:00

Share This Post, Choose Your Platform!

About the Author: